23andMe Co-founder & CEO Anne Wojcicki says weve only seen the tip of the iceberg for human genomics and DNA research.
Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome, Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California.
Wojcicki says shes disappointed in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome.
I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.
The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the companys partnership with GlaxoSmithKline (GSK) ends in July.
Interview Highlights:
1:29
How genetics can tell us more about human diversity
2:20
Why 23andMe CEO is disappointed about genome adoption
5:00
Wojcicki on 23andMe partnership with pharma giant GSK
7:15
Genetics needs to be part of medical school training
8:26
Whats next for 23andMe
BRIAN SOZZI: I'm really interested in what 23 is-- 23andMe is working on at this point in its life. But you have said, you see the world through the lens of genetics. What is this world telling you right now?
ANNE WOJCICKI: Oh. Well, genetics-- so I should say, we're on the 20th anniversary of when the first human genome was sequenced. And it has, you know, it's a big milestone of like when it costs billions of dollars to get a single person sequenced and what you can learn from that to where we are today, where 23andMe has over 13 million people. You can learn a tremendous amount from your genome. And you can start to account for like all of this incredible diversity we see in life and all of the variation we have in our health, and like why some people do so well on a treatment, why some people don't, why some people get a disease, why some people don't.
Story continues
So I'm excited about the 20th anniversary and like, where it can go from here. But I do look at everything with that perspective of genetics, because it's almost like a digital code way of looking at all of the diversity that we see in life. And I look around a room, and I do think about like, I look at your eyes right now, and I'm like, ah--
[LAUGHTER]
I know he's an AG.
BRIAN SOZZI: What's AG?
ANNE WOJCICKI: It's just me, like you have like greenish eyes.
BRIAN SOZZI: Ha, what does that say about my DNA?
ANNE WOJCICKI: Well, just like you're not a GG.
BRIAN SOZZI: OK. Is one better than the other?
ANNE WOJCICKI: No, no. It's all-- no, that's the thing about diversity. Like, it's not-- you know, the diversity that we have of humans is about our story of survival, which is like a really beautiful story of like how we as, like, humans are made to keep living on this planet. Like, some people are made for cold, some people are made for hot. Some people have darker skin, and that protects them from sun. Some people are fair skin, and they can absorb more sun. Like, it's just like diversity is amazing.
BRIAN SOZZI: I wasn't going to go here, but are you a-- when you go into a room, are you assessing people like this? I didn't even realize anything. You just told me.
ANNE WOJCICKI: [LAUGHS]
[INTERPOSING VOICES]
[LAUGHTER]
ANNE WOJCICKI: I mean, I do-- I do sometimes see people, then I'm like, and they'll say, they're like, oh, yeah, I haven't done 23andMe yet. And I'll be kind of chomping at the bit. I'd be like I'm dying to see your DNA.
BRIAN SOZZI: Wow. OK, let me go-- let me get back on topic here. We're at the Milken Conference. And there's so much focus on health care because of the efforts by Michael Milken. I went to the doctor recently, just a checkup, didn't tell me anything about my genetics. Didn't even tell me where I can go, what I can do, what I may not do. Is it-- is it interwoven in health care right now? Or is there something missing here?
ANNE WOJCICKI: No. I mean, again, I'd say that's the disappointment I have of the 20 years having been around when they first sequenced the human genome that it's not broadly adopted. And I think part of that reason is that genetics tells you a lot about what you're at risk for. And it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.
And so that's frankly it's my disappointment here is that we don't look at genetics, for instance, when you're getting a prescription and say, like, are you likely to respond? Should you have a different dose? You look at the epidemic of depression. There's all kinds of, you know, you can look at your genetics, look at a number of the drug, you know, interaction genes and see what medication you're likely to most respond to.
It's a tragedy to me that people are not first tested before they are prescribed something. I think also there's all kinds of other conditions like hereditary, you know, colon cancer. People should actually know whether or not they have something like that. And they can have increased screening. Familial hypercholesterolemia is where you have like really high, you know, cholesterol levels, and you need to get screened.
So things like that you could actually really start to, you know, see it for yourself.
BRIAN SOZZI: All of that makes a lot of sense to me.
ANNE WOJCICKI: Yeah.
BRIAN SOZZI: What's the biggest roadblock preventing health care from adopting these things?
ANNE WOJCICKI: It's a good question. I'd say there's two things. Like, one is it's not in the workflow. So meaning like when you go to your doctor, it's not necessarily part of the workflow, the processes. Like, if you said you're interested in having children, it isn't necessarily part of that workflow for actually how your doctor would follow up, how insurance would pay-- be paid. Does the doctor-- is the doctor educated about genetics? And what, you know, why they should do it, what you're potentially going to learn, how to potentially deal with the results if they get them.
I think for a long time we were really just used to genetic counselors and saying, like, hey, it's going to be put on a genetic counselor if you have this particular issue. And more and more, it's going into the mainstream. It should be your primary care physician really integrating it with primary care.
So I think that insurance and payment is a big obstacle. And I would say that physician education is a main-- is a significant obstacle as well as like being part of the workflow.
BRIAN SOZZI: Last time you talked to you around the time of the IPO 2021, you were just starting, I guess, getting going on a partnership with GSK and drug development. Where is that now? And when is that first drugs from this deal coming to market?
ANNE WOJCICKI: Well, that is thriving. GSK is actually-- it's done extraordinarily well. We have over 50 programs underway with GSK. We do have one that is in a phase I study that GSK now controls. We've-- it's co-developed, but we-- they're taking lead now. So, and there's a huge number of programs behind it.
23andMe also has our own wholly owned program. It's an immunotherapy program. So super excited about it. It is definitely exciting to see that you can go from understanding the genetic variation-- that makes me so excited-- to saying, wow, some people are, you know, genetically not likely to develop, you know, a certain kind of condition. And then can I understand that and turn that actually into a drug to help either treat people who have that condition?
BRIAN SOZZI: Is that the holy grail in health care, looking out over the next decade, the ability to match up your genetics with figuring out the cure for cancer or some other disease?
ANNE WOJCICKI: I look at all the explosion of all these new technologies with gene therapy, with CRISPR, with RNA technologies, and understanding the human genome. And I think what 23andMe can really bring to the table here is the understanding of the human genome.
So for instance, one thing that we can do really well is we study healthy people, meaning that you might have a particularly interesting mutation that the scientific world thinks like they don't know. Maybe it's potentially disease-causing. But because I can study you, and I can say, OK, you have finished a knockout mutation, you're doing really well. You have no other health issues.
We potentially know that that, like, changing that or modifying that gene is not going to create any other kinds of issues. So it's a way to help the pharmaceutical industry study essentially what's naturally going on in humans. So we find like studying huge populations and huge numbers helps us just understand that natural variability in people.
BRIAN SOZZI: How do you-- how do you go about championing this in the educational system? Do you see the things you're talking about today being embedded in our education system?
ANNE WOJCICKI: I think that, you know, genetics to be really successful, I think it needs to be part of medical school training. And it needs to be integrated not as a single subject but throughout all aspects of the curriculum. So when you're doing, you know, cardiovascular health, that it's part of that. When you're doing renal health, it's part of that.
That everything, every aspect of health care has a genetic component and helping realize, you know, the personalization that comes with it. Like, every patient that is coming also is unique and different. And so we're all going to metabolize drugs in a different way. You're going to have potentially, like, your blood values are naturally going to be different than my blood values based on your genetics.
There's just a lot of variability that we're going to understand from your genetics. And that's going to manifest in different ways in each of us. So what your baseline is going to be different than what my baseline is. So I do see that it needs to be integrated throughout all aspects of health care, not just as a specialty in genetics.
BRIAN SOZZI: Lastly, what's next for your company?
ANNE WOJCICKI: I'm excited-- there's two big areas. One is consumer, which is really about helping. We have over 13 million people and helping them do more with the information that we already provided. So one thing that we've gotten the feedback from our customers. Is that it's almost an overwhelming amount of information. So how do you translate all this into a care plan?
And there's a lot of lifestyle information we're also collecting from our customers about how they eat, how much they sleep, how much they walk, exercise, happiness. So helping people understand their health in the context of what they've self-reported, their genetics, and then all of their lifestyle information, so that then you can know what things should you change. And some of that might be more proactive screening in the medical system. Some of it might be changing how you sleep. Some of it might be changing how you eat.
So I see a real opportunity for us to deliver a type of personalized prevention that's grounded in your genetics. But we take all that other information about you. And we really help you be as healthy as you can.
I think the second slide, I think, we see this from the work that we've done with GSK. Having a large-- you know, a large amount of genetic information with really, really broad phenotypic data is incredibly powerful for drug discovery. And the end of the GSK collaboration comes in July. And it opens up all kinds of doors for us to, you know, start to do more partnerships with more companies. And I feel a responsibility to my customers that if you're somebody who has a family history of Alzheimer's, it's on me.
Follow this link:
Why the human genome could be healthcares holy grail - Yahoo Finance
- The complete plastome sequences of invasive weed Parthenium hysterophorus: genome organization, evolutionary ... - Nature.com - February 18th, 2024 [February 18th, 2024]
- Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with ... - Journal of Translational... - February 18th, 2024 [February 18th, 2024]
- Polymerase Chain Reaction (PCR) - National Human Genome Research Institute - February 18th, 2024 [February 18th, 2024]
- Genomic Time Machine Reveals Secrets of Human DNA - SciTechDaily - February 18th, 2024 [February 18th, 2024]
- 1 Million Unannotated Exons Discovered in the Human Genome - Technology Networks - February 18th, 2024 [February 18th, 2024]
- Hope for the night parrot: bird's full genome has been sequenced - Cosmos - February 18th, 2024 [February 18th, 2024]
- RevIT AAV Enhancer: Rev-up AAV genome production in upstream manufacturing - BioProcess Insider - February 18th, 2024 [February 18th, 2024]
- Multi-omics resources for the Australian southern stuttering frog (Mixophyes australis) reveal assorted antimicrobial ... - Nature.com - February 18th, 2024 [February 18th, 2024]
- Large-scale gene expression alterations introduced by structural variation drive morphotype diversification in Brassica ... - Nature.com - February 18th, 2024 [February 18th, 2024]
- Near-gapless and haplotype-resolved apple genomes provide insights into the genetic basis of rootstock-induced ... - Nature.com - February 18th, 2024 [February 18th, 2024]
- Secrets of Night Parrot unlocked after first genome sequenced - CSIRO - February 18th, 2024 [February 18th, 2024]
- CRISPR gene editing tool gets a revolutionary high-tech upgrade - Earth.com - February 18th, 2024 [February 18th, 2024]
- Ancient retroviruses played a key role in the evolution of vertebrate brains - EurekAlert - February 18th, 2024 [February 18th, 2024]
- Natural selection and genetic diversity maintenance in a parasitic wasp during continuous biological control application - Nature.com - February 18th, 2024 [February 18th, 2024]
- Hopes elusive parrots genome will provide answers - news.com.au - February 18th, 2024 [February 18th, 2024]
- MicroRNA is the master regulator of the genome researchers are learning how to treat disease by harnessing the ... - The Conversation - November 30th, 2023 [November 30th, 2023]
- "Ground-Breaking" Release of World's Largest Whole Genome Resource - Inside Precision Medicine - November 30th, 2023 [November 30th, 2023]
- Pangenome analysis reveals genomic variations associated with domestication traits in broomcorn millet - Nature.com - November 30th, 2023 [November 30th, 2023]
- Global genetic diversity, introgression, and evolutionary adaptation of indicine cattle revealed by whole genome ... - Nature.com - November 30th, 2023 [November 30th, 2023]
- Genome characteristics of atypical porcine pestivirus from abortion cases in Shandong Province, China - Virology Journal - Virology Journal - November 30th, 2023 [November 30th, 2023]
- Correcting modification-mediated errors in nanopore sequencing by nucleotide demodification and reference-based ... - Nature.com - November 30th, 2023 [November 30th, 2023]
- CRISPR-Based "Genome Shredding" Technique Shows Promise in Treating Glioblastoma - Inside Precision Medicine - November 30th, 2023 [November 30th, 2023]
- Genome wide analysis revealed conserved domains involved in the effector discrimination of bacterial type VI secretion ... - Nature.com - November 30th, 2023 [November 30th, 2023]
- TRISH to investigate the effects of spaceflight on the human genome, central nervous system - Odessa American - November 30th, 2023 [November 30th, 2023]
- The venom preceded the stinger: Genomic studies shed light on the origins of bee venom - EurekAlert - November 30th, 2023 [November 30th, 2023]
- Integrating genomic and multiomic data for Angelica sinensis provides insights into the evolution and biosynthesis of ... - Nature.com - November 30th, 2023 [November 30th, 2023]
- Genetic diversity and ancestry of the Khmuic-speaking ethnic groups ... - Nature.com - September 21st, 2023 [September 21st, 2023]
- Researchers to Apply Genome Analysis to Childhood Cancers; Goal ... - The Japan News - September 21st, 2023 [September 21st, 2023]
- How Bats' Genomes May Help Them Avoid Cancer and Survive ... - Technology Networks - September 21st, 2023 [September 21st, 2023]
- Longitudinal genomic surveillance of carriage and transmission of ... - Nature.com - September 21st, 2023 [September 21st, 2023]
- Whole genomes from bacteria collected at diagnostic units around ... - Nature.com - September 21st, 2023 [September 21st, 2023]
- Genome-wide identification of lncRNA & mRNA for T2DM | PGPM - Dove Medical Press - September 21st, 2023 [September 21st, 2023]
- Tasmanian tiger RNA is first to be recovered from an extinct animal - Nature.com - September 21st, 2023 [September 21st, 2023]
- Loneliness and depression: bidirectional mendelian randomization ... - Nature.com - September 21st, 2023 [September 21st, 2023]
- Rome Therapeutics adds $72 million to Series B round to harness ... - OutSourcing-Pharma.com - September 21st, 2023 [September 21st, 2023]
- Mystery of 'living fossil' tree frozen in time for 66 million years finally ... - Livescience.com - September 21st, 2023 [September 21st, 2023]
- Scientists Compare Genomes of 240 Mammals to Understand Human DNA - The New York Times - May 4th, 2023 [May 4th, 2023]
- Genomes From 240 Mammalian Species Help Explain 100 Years Of Evolution And Human Disease - ABP Live - May 4th, 2023 [May 4th, 2023]
- 'Deletions' from the human genome may be what made us human - Yale News - May 4th, 2023 [May 4th, 2023]
- GeneDx Adds Buccal Swab as Non-Invasive Whole Genome ... - GlobeNewswire - May 4th, 2023 [May 4th, 2023]
- Whole-genome sequencing used to track down genes behind familial glioma - Medical Xpress - May 4th, 2023 [May 4th, 2023]
- Wiggly proteins guard the genome: Dynamic network in the pores of ... - Science Daily - May 4th, 2023 [May 4th, 2023]
- Genome-Wide Splicing Quantitative Expression Locus Analysis ... - Cancer Discovery - May 4th, 2023 [May 4th, 2023]
- Digital Genome Market is expand at a CAGR of 8.6% to reach USD ... - Digital Journal - May 4th, 2023 [May 4th, 2023]
- High School Students Learn the Basics of Base Editing to Cure GFP ... - University of California San Diego - May 4th, 2023 [May 4th, 2023]
- Genomic researchers gain access to CSIRO's AI-powered data ... - Microsoft - May 4th, 2023 [May 4th, 2023]
- Archaic hominin traits through the splicing lens - Nature.com - May 4th, 2023 [May 4th, 2023]
- Critical bug in genome sequencing device scores '10' on CVSS ratings - SC Media - May 4th, 2023 [May 4th, 2023]
- Novel Genomic Approach Ensures Better Diagnosis of Hereditary ... - Technology Networks - May 4th, 2023 [May 4th, 2023]
- Intellia Therapeutics: Leading the Way in Revolutionary Genome ... - Best Stocks - May 4th, 2023 [May 4th, 2023]
- Visual tracking of viral infection dynamics reveals the synergistic ... - Nature.com - May 4th, 2023 [May 4th, 2023]
- Genome | Genome LLC | United States - March 31st, 2023 [March 31st, 2023]
- Belarus: EU and WHO deliver equipment for research of genomes of infectious disease agents - EIN News - February 24th, 2023 [February 24th, 2023]
- Gene vs. genome: Definition, function, and impact - January 30th, 2023 [January 30th, 2023]
- Big cog in the wheel: As Covid worries reappear, Insacogs genome sequencing ability must be aided by govts - Times of India - December 25th, 2022 [December 25th, 2022]
- CapitalGainsReport Sector Spotlight: Healthcare Penny Stocks On The Move (ARDX, WHSI, BNGO) - Marketscreener.com - November 25th, 2022 [November 25th, 2022]
- Genome Insight and Kun-hee Lee Child Cancer & Rare Disease Project Team of SNUH (Seoul National University Hospital) Made an Agreement About a... - November 23rd, 2022 [November 23rd, 2022]
- Genome-wide association study reveals distinct genetic associations related to leaf hair density in two lineages of wheat-wild relative Aegilops... - October 19th, 2022 [October 19th, 2022]
- The Global Genomics Market to Exhibit Growth at a CAGR of 16.90% During the Forecast Period (20222027) | DelveInsight - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Superresolution Method Poised to Better Gene Function Understanding - Photonics.com - October 19th, 2022 [October 19th, 2022]
- Genome-centric analysis of short and long read metagenomes reveals uncharacterized microbiome diversity in Southeast Asians - Nature.com - October 15th, 2022 [October 15th, 2022]
- How a New Battery Data Genome Project Will Use Vast Amounts of Information to Build Better EVs - InsideClimate News - October 15th, 2022 [October 15th, 2022]
- Scientists Reconstruct the Genome of the 180-Million-Year-Old Common Ancestor of All Mammals - SciTechDaily - October 15th, 2022 [October 15th, 2022]
- Combining OSMAC, metabolomic and genomic methods for the production and annotation of halogenated azaphilones and ilicicolins in termite symbiotic... - October 15th, 2022 [October 15th, 2022]
- Concerted expansion and contraction of immune receptor gene repertoires in plant genomes - Nature.com - October 15th, 2022 [October 15th, 2022]
- Uncovering the Full Variant Continuum with Pioneering Solutions from Bionano - Inside Precision Medicine - October 15th, 2022 [October 15th, 2022]
- Metagenomic analysis of viromes in tissues of wild Qinghai vole from the eastern Tibetan Plateau | Scientific Reports - Nature.com - October 15th, 2022 [October 15th, 2022]
- Research Assistant in Molecular and Genome Editing Therapeutics job with KINGS COLLEGE LONDON | 311876 - Times Higher Education - October 15th, 2022 [October 15th, 2022]
- Lessons learnt from COVID-19 shed light on future pandemic preparedness - The Peter Doherty Institute for Infection and Immunity - October 15th, 2022 [October 15th, 2022]
- From Neanderthal genome to Nobel prize: meet geneticist Svante Pbo - Nature.com - October 8th, 2022 [October 8th, 2022]
- Revealing the genome organization of the earliest common ancestor of all mammals - Tech Explorist - October 8th, 2022 [October 8th, 2022]
- Mitochondrial DNA Is Working Its Way Into the Human Genome - Technology Networks - October 8th, 2022 [October 8th, 2022]
- Animated Map: Where to Find Water on Mars - Visual Capitalist - October 8th, 2022 [October 8th, 2022]
- Reconstruction of The First Mammal's Genome Suggests It Had 38 Chromosomes - ScienceAlert - October 6th, 2022 [October 6th, 2022]
- Genomic Science Breakthroughs Are Happening Faster Than Ever Thanks to HPC - CIO - October 6th, 2022 [October 6th, 2022]
- Genome Of Ancient Humans Is The Winning Field Of 2022's Nobel Prize in Medicine - IFLScience - October 6th, 2022 [October 6th, 2022]
- ASU professor to study new genome editing tools with NIH Innovator Award - ASU News Now - October 6th, 2022 [October 6th, 2022]
- New R&D norms to fast-track research on genome-edited crops - The Financial Express - October 6th, 2022 [October 6th, 2022]
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 6th, 2022 [October 6th, 2022]